scPharmaceuticals Q2 EPS $(0.36) Beats $(0.37) Estimate
Portfolio Pulse from Benzinga Newsdesk
scPharmaceuticals reported Q2 losses of $(0.36) per share, beating the analyst consensus estimate of $(0.37) by 2.7 percent. However, this is a 2.86 percent decrease over losses of $(0.35) per share from the same period last year.
August 10, 2023 | 8:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
scPharmaceuticals' Q2 losses were less than expected, but still represent a YoY decrease.
While scPharmaceuticals beat the analyst consensus estimate for Q2 losses, the fact that these losses represent a YoY decrease could have a neutral impact on the stock. Investors may be encouraged by the better-than-expected results, but concerned about the company's profitability.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100